Angiotensin-Converting Enzyme Inhibitors - Inhibit the conversion of AngI to AngII Captopril, Lisinopril Losartan, Valsartan, Eprosartan
OBJECTIVE:To provide clinical support that conversion from Captopril to lisinopril at a daily oral dosage ratio of 5:1 maintains comparable therapeutic efficacy, and to estimate retrospectively cost savings because of conversion from Captopril to lisinopril therapy at the study site and with the associated overall drug conversion program instituted by Kaiser Permanente.DESIGN:An open-label
Angiotensin converting enzyme (ACE) inhibitors, such as lisinopril, enalapril, ramipril, benazepril, and captopril, block the conversion of
A captopril conversion rate of 3 mg captopril to 1 mg lisinopril was used. This study demonstrated that utilizing a conversion rate of 3 mg of captopril to 1 mg of lisinopril can be considered safe and effective for management of hypertension after cardiothoracic surgery in children less than 7 years of age.
Most angiotensin converting enzyme inhibitors are prodrugs, requiring hepatic conversion to an active metabolite. Captopril and lisinopril are
Captopril and lisinopril are the only ACE inhibitors that do not require hepatic conversion to active metabolites and may be preferred in
Angiotensin converting enzyme (ACE) inhibitors, such as lisinopril, enalapril, ramipril, benazepril, and captopril, block the conversion of
Captopril and enalapril are approved for infants and children; however, lisinopril is only approved for 7 years of age. This study evaluated safety and efficacy of converting from captopril to lisinopril in patients utilizing a pre-defined conversion of 3 mg captopril to 1 mg lisinopril.
Angiotensin converting enzyme (ACE) inhibitors, such as lisinopril, enalapril, ramipril, benazepril, and captopril, block the conversion of
Comments